Brokerages Set Semler Scientific Inc. (NASDAQ:SMLR) PT at $74.25

Semler Scientific Inc. (NASDAQ:SMLR) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $74.25.

Several research firms have weighed in on SMLR. Maxim Group cut their target price on shares of Semler Scientific from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, September 19th. Weiss Ratings cut Semler Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. Benchmark lowered their price target on Semler Scientific from $101.00 to $86.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Finally, Cantor Fitzgerald cut their price objective on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, August 6th.

Semler Scientific Trading Up 9.8%

NASDAQ SMLR opened at $20.88 on Friday. Semler Scientific has a 12 month low of $17.41 and a 12 month high of $81.56. The stock has a 50-day simple moving average of $26.45 and a 200 day simple moving average of $32.63. The company has a current ratio of 1.97, a quick ratio of 1.95 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $316.54 million, a PE ratio of 7.51 and a beta of 1.44.

Semler Scientific (NASDAQ:SMLR) last issued its earnings results on Wednesday, November 12th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $1.21. The firm had revenue of $7.49 million for the quarter, compared to analysts’ expectations of $7.87 million. Semler Scientific had a return on equity of 34.21% and a net margin of 130.80%.

Institutional Investors Weigh In On Semler Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Semler Scientific by 9.5% in the 3rd quarter. Vanguard Group Inc. now owns 700,505 shares of the company’s stock valued at $21,015,000 after acquiring an additional 61,037 shares in the last quarter. Raymond James Financial Inc. raised its stake in shares of Semler Scientific by 211.8% in the 3rd quarter. Raymond James Financial Inc. now owns 253,977 shares of the company’s stock valued at $7,619,000 after purchasing an additional 172,527 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Semler Scientific by 26.1% in the second quarter. Geode Capital Management LLC now owns 215,104 shares of the company’s stock valued at $8,335,000 after purchasing an additional 44,470 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Semler Scientific by 226.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 158,576 shares of the company’s stock worth $5,740,000 after buying an additional 109,951 shares during the period. Finally, RFG Advisory LLC acquired a new position in shares of Semler Scientific during the third quarter worth about $3,441,000. 49.37% of the stock is currently owned by institutional investors and hedge funds.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.